Atazanavir

also known as ATV · Reyataz · ATZ · atazanavir/r · Atazanavir Sulphate · Atazanavir-ritonavir · BMS-232632 · Atazanavir (as sulfate) · +13 more

Other / unclassified targets UGT1A1 via inhibition

Developed for: HIV infectious disease · AIDS · hyperlipidemia · COVID-19 · lipodystrophy · fibrotic liver disease · HIV wasting syndrome · immunodeficiency-related disorder
+4 more
· severe acute respiratory syndrome · type 1 diabetes mellitus · type 2 diabetes mellitus · AIDS dysmorphic syndrome
Investigated by: Bristol-Myers Squibb · National Institute of Allergy and Infectious Diseases (NIAID) · Gilead Sciences · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · GlaxoSmithKline · Merck Sharp & Dohme LLC
+102 more
· ANRS, Emerging Infectious Diseases · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Hoffmann-La Roche · Radboud University Medical Center · University of Liverpool · ViiV Healthcare · Abbott · Boehringer Ingelheim · Brigham and Women's Hospital · Community Research Initiative of New England · European and Developing Countries Clinical Trials Partnership (EDCTP) · Fight AIDS and Infectious Diseases Foundation · French National Agency for Research on AIDS and Viral Hepatitis · Germans Trias i Pujol Hospital · International Maternal Pediatric Adolescent AIDS Clinical Trials Group · Juan A. Arnaiz · National Health Security Office, Thailand · National Institutes of Health (NIH) · Obafemi Awolowo University · St Stephens Aids Trust · The HIV Netherlands Australia Thailand Research Collaboration · Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA · University of California, San Francisco · University of Turin, Italy · Acrotech Biopharma Inc. · African Centre of Excellence for Genomics of Infectious Diseases · Analysis Group, Inc. · Asan Medical Center · Axis Clinicals Limited · Biomed Industries, Inc. · CIHR Canadian HIV Trials Network · Case Western Reserve University · Castagna Antonella · Catholic University of the Sacred Heart · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Clinical Alliance for Research & Education - Infectious Diseases, LLC. · Dutch Diabetes Research Foundation · Fogarty International Center of the National Institute of Health · Foundation for Cardiovascular Research, Zurich · Fundacion Clinic per a la Recerca Biomédica · HIV Prevention Trials Network · Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic · Harvard Medical School (HMS and HSDM) · Hospital Clinic of Barcelona · Hospital San Jaime de Calella · Hospital Universitari Vall d'Hebron Research Institute · Hospital do Coracao · Hospitales Universitarios Virgen del Rocío · INSERM UMR S 1136 · IRCCS San Raffaele · Imperial College London · Indiana University · Infectious Disease Hospital Olodo · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · Institute of Tropical Medicine, Belgium · International Antiviral Therapy Evaluation Center · International Medical Center of Japan · IrsiCaixa · Janssen R&D Ireland · Joint Clinical Research Centre, Kampala, Uganda · Judit Pich · Kenneth H. Mayer, MD · Kirby Institute · Ludwig-Maximilians - University of Munich · Makerere University · McGill University Health Centre/Research Institute of the McGill University Health Centre · Ministry of Health, Labour and Welfare, Japan · Mylan Laboratories · NIH Office of AIDS Research (OAR) · NIMR-Mbeya Medical Research Program (MMRP)/ Mbeya Referral Hospital, Tanzania · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Institute of Mental Health (NIMH) · National Institute of Neurological Disorders and Stroke (NINDS) · all 108 on the full record

Regulatory milestones approvals, filings & regulatory actions · 11 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (9)	US (FDA)	REYATAZ	—	2004-07-06 – 2017-05-23	fda.gov ↗
Approved	EU (EMA)	Reyataz	—	2004-03-01	europa.eu ↗
Approved	US (FDA)	REYATAZ	—	2003-06-20	fda.gov ↗

Trials 109 · started per year

today

US approved 2003

EU approved 2004

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 122 trials
Phase 1	NCT05236738	May → Jul 2022	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT04263350	Feb → Nov 2020	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT04184869	Aug 2019 → Dec 2022	cancer, hematopoietic and lymphoid cell neoplasm	Acrotech Biopharma Inc.	Completed	No outcome recorded
Phase 1	NCT02565888	Nov 2015 → Jan 2016	HIV infectious disease, hepatitis C virus infection	Radboud University Medical Center	Completed	No outcome recorded
Phase 1	NCT02589158	Nov 2015 → Mar 2016	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 1	NCT02307656	Dec 2014 → Sep 2021	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02034838	Jan → Nov 2014	HIV infectious disease	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 1	NCT01818856	Dec 2012 → Apr 2013	HIV infectious disease, chronic hepatitis C virus infection	Hospitales Universitarios Virgen del Rocío	Completed	No outcome recorded
Phase 1	NCT01421355	May 2012 → Feb 2014	type 1 diabetes mellitus	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 1	NCT01592305	May → Jun 2012	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT01591850	Sep → Nov 2011	—	Hoffmann-La Roche	Completed	No outcome recorded
Phase 1	NCT01368783	Jun 2011 → ?	—	Asan Medical Center	Unknown	No outcome recorded
Phase 1	NCT01073761	Apr → Jun 2010	HIV infectious disease	St Stephens Aids Trust	Completed	No outcome recorded
Phase 1	NCT00883935	Apr → Jun 2009	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00878306	Nov 2008 → Apr 2013	HIV infectious disease, substance abuse	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT00357604	Jul → Nov 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00326716	Jun 2006 → Jan 2009	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00162149	Oct 2005 → Jul 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00307502	Jan 2005 → Dec 2009	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 1	NCT02253836	Jan → Jul 2005	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00135434	Sep 2004 → Jun 2005	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT02257008	Mar → Dec 2003	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 1/23 trials
Phase 1/2	NCT01565889	Mar 2012 → Aug 2013	HIV infectious disease, hepatitis C virus infection	Gilead Sciences	Completed	No outcome recorded
Phase 1/2	NCT00260078	Feb 2006 → Apr 2009	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT00006604	Nov 2000 → Oct 2011	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 216 trials
Phase 2	NCT04459286	Oct 2020 → May 2021	COVID-19	Obafemi Awolowo University	Terminated	No outcome recorded
Phase 2	NCT02542852	Sep 2015 → Jun 2016	HIV infectious disease	Castagna Antonella	Completed	No outcome recorded
Phase 2	NCT02566707	Aug 2015 → Dec 2016	HIV infectious disease	Radboud University Medical Center	Terminated	No outcome recorded
Phase 2	NCT02386098	Jul 2015 → Jun 2017	HIV infectious disease	ViiV Healthcare	Terminated	No outcome recorded
Phase 2	NCT02473328	Jun 2015 → Dec 2017	HIV infectious disease	Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida	Completed	No outcome recorded
Phase 2	NCT01903031	Dec 2014 → Oct 2016	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 2	NCT01231685	Dec 2011 → Mar 2016	HIV infectious disease, fibrotic liver disease, hepatitis C virus infection	McGill University Health Centre/Research Institute of the McGill University Health Centre	Completed	No outcome recorded
Phase 2	NCT01656109	Jul 2011 → Feb 2013	HIV infectious disease	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded
Phase 2	NCT00896051	Aug 2009 → Apr 2012	AIDS	Janssen R&D Ireland	Completed	No outcome recorded
Phase 2	NCT00820118	May 2009 → May 2012	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 2	NCT00696722	Jun 2008 → Mar 2009	type 2 diabetes mellitus	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT00528060	Jan → Nov 2008	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded
Phase 2	NCT00122577	Mar 2002 → Jul 2004	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Terminated	No outcome recorded
Phase 2	NCT00004584	Dec 1999 → Jan 2002	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT00002240	Mar 1999 → Dec 2001	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 2	NCT00007202	? → Oct 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/35 trials
Phase 2/3	NCT04452565	Jun 2022 → Dec 2023	severe acute respiratory syndrome	Biomed Industries, Inc.	Unknown	No outcome recorded
Phase 2/3	NCT04468087	Feb → Aug 2021	COVID-19	Hospital do Coracao	Completed	No outcome recorded
Phase 2/3	NCT04121195	Oct 2020 → May 2022	HIV infectious disease, tuberculosis	University of Liverpool	Completed	No outcome recorded
Phase 2/3	NCT02016924	Jan 2014 → Jun 2025 overdue	AIDS	Gilead Sciences	Active not recruiting	No outcome recorded
Phase 2/3	NCT00624195	Mar 2007 → Feb 2012	HIV infectious disease	University of California, San Diego	Completed	No outcome recorded
Phase 320 trials
Phase 3	NCT04022967	Sep 2020 → Feb 2025	HIV infectious disease	ANRS, Emerging Infectious Diseases	Unknown	No outcome recorded
Phase 3	NCT03708861	Jan 2016 → Dec 2017	HIV infectious disease	University of Turin, Italy	Withdrawn	No outcome recorded
Phase 3	NCT01605084	Jun 2012 → Aug 2014	HIV infectious disease	Bristol-Myers Squibb	Withdrawn	No outcome recorded
Phase 3	NCT01255371	Mar 2012 → May 2013	HIV infectious disease	ANRS, Emerging Infectious Diseases	Withdrawn	No outcome recorded
Phase 3	NCT01335698	May 2011 → Sep 2014	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT01099579	Oct 2010 → Oct 2012	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT01511809	Sep 2010 → Jul 2013	HIV infectious disease	IRCCS San Raffaele	Completed	No outcome recorded
Phase 3	NCT00811954	May 2009 → Jun 2013	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 3	NCT00440947	Mar 2007 → Jul 2010	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT00337467	Jun 2006 → May 2008	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00280969	Sep 2005 → Sep 2009	HIV infectious disease	International Medical Center of Japan	Completed	No outcome recorded
Phase 3	NCT00118898	Sep 2005 → Nov 2009	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 3	NCT00225017	Jun 2005 → Jun 2008	HIV infectious disease, hyperlipidemia	Northwestern University	Completed	No outcome recorded
Phase 3	NCT00074581	Feb 2005 → May 2015	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00160329	Jan 2004 → Apr 2007	HIV infectious disease, hyperlipidemia	Stanford University	Completed	No outcome recorded
Phase 3	NCT01003990	Oct 2002 → Feb 2016	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00028067	Aug 2001 → Apr 2002	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 3	NCT00013897	Feb 2001 → Apr 2003	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00028301	Feb 2001 → Sep 2003	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00013520	? → Jun 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 433 trials
Phase 4	NCT06337032	Aug 2024 → Mar 2034 expected	HIV infectious disease	Gilead Sciences	Recruiting	No outcome recorded
Phase 4	NCT04311957	Sep 2020 → May 2022	HIV infectious disease	Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic	Unknown	No outcome recorded
Phase 4	NCT04531072	Sep 2018 → May 2019	—	Fogarty International Center of the National Institute of Health	Completed	No outcome recorded
Phase 4	NCT02513147	Jun 2015 → Nov 2016	—	Hospital Universitari Vall d'Hebron Research Institute	Completed	No outcome recorded
Phase 4	NCT02246998	Dec 2014 → Jan 2016	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT01367236	Jan 2013 → Oct 2015	HIV infectious disease, cognitive disorder	Imperial College London	Completed	No outcome recorded
Phase 4	NCT01602822	Feb → May 2012	HIV infectious disease	Kenneth H. Mayer, MD	Terminated	No outcome recorded
Phase 4	NCT01351740	Jul 2011 → Jan 2015	HIV infectious disease	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT01159223	May 2011 → Dec 2014	HIV infectious disease	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded
Phase 4	NCT01274780	May 2011 → May 2013	—	Juan A. Arnaiz	Completed	No outcome recorded
Phase 4	NCT01928407	Feb → Mar 2011	HIV infectious disease, immunodeficiency-related disorder	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	Completed	No outcome recorded
Phase 4	NCT01232127	Feb → Jun 2011	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT01194856	Oct 2010 → Dec 2011	HIV infectious disease, mitochondrial disease	The Cleveland Clinic	Terminated	No outcome recorded
Phase 4	NCT00955968	Jan 2010 → Aug 2016	HIV infectious disease	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	Completed	No outcome recorded
Phase 4	NCT00931801	Dec 2009 → Feb 2012	HIV infectious disease	Community Research Initiative of New England	Completed	No outcome recorded
Phase 4	NCT00940771	Aug 2009 → Oct 2013	HIV infectious disease	Phoenix Children's Hospital	Completed	No outcome recorded
Phase 4	NCT00885482	May 2009 → May 2010	HIV infectious disease	Catholic University of the Sacred Heart	Completed	No outcome recorded
Phase 4	NCT00869960	Mar 2009 → Dec 2010	—	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 4	NCT00757783	Oct 2008 → Aug 2009	HIV infectious disease	Tibotec, Inc	Completed	No outcome recorded
Phase 4	NCT00756730	Sep 2008 → Jun 2011	HIV infectious disease	Community Research Initiative of New England	Completed	No outcome recorded
Phase 4	NCT00751153	Mar 2008 → Oct 2009	HIV infectious disease	Peter J. Ruane, M.D., Inc.	Unknown	No outcome recorded
Phase 4	NCT00532168	Sep 2007 → Dec 2012	HIV infectious disease	Juan A. Arnaiz	Completed	No outcome recorded
Phase 4	NCT00420355	Apr → Oct 2007	HIV infectious disease	University of Oklahoma	Terminated	No outcome recorded
Phase 4	NCT00355719	Jan 2007 → Feb 2008	HIV infectious disease	Germans Trias i Pujol Hospital	Completed	No outcome recorded
Phase 4	NCT00426296	Aug 2006 → ?	HIV infectious disease, lipodystrophy	Clinical Alliance for Research & Education - Infectious Diseases, LLC.	Unknown	No outcome recorded
Phase 4	NCT00389402	Jul 2006 → Jul 2008	HIV infectious disease	International Antiviral Therapy Evaluation Center	Completed	No outcome recorded
Phase 4	NCT00385645	May 2006 → Aug 2009	HIV infectious disease	Hospital Clinic of Barcelona	Completed	No outcome recorded
Phase 4	NCT00207142	Nov 2005 → Aug 2007	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT00224445	Sep 2005 → Jan 2007	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 4	NCT00312754	Jun 2005 → Apr 2007	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 4	NCT00084136	May 2005 → May 2010	HIV infectious disease	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	Completed	No outcome recorded
Phase 4	NCT00447070	Aug 2004 → May 2006	HIV infectious disease, hyperlipidemia	Foundation for Cardiovascular Research, Zurich	Completed	No outcome recorded
Phase 4	NCT00082394	Apr 2004 → Mar 2006	HIV infectious disease	GlaxoSmithKline	Completed	No outcome recorded

Phase not applicable9 trials
—	NCT05680792	Sep 2020 → Jan 2023	—	Obafemi Awolowo University	Completed	No outcome recorded
—	NCT02652793	Nov 2015 → Nov 2018	HIV infectious disease	Judit Pich	Completed	No outcome recorded
—	NCT00814879	May 2009 → May 2013	AIDS	Yale University	Completed	No outcome recorded
—	NCT00884793	Sep 2008 → Dec 2009	HIV infectious disease	University of California, San Francisco	Completed	No outcome recorded
—	NCT00084019	Jul 2004 → May 2006	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00525239	Mar 2004 → Dec 2010	HIV infectious disease	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Unknown	No outcome recorded
—	NCT00720590	Nov 2003 → Sep 2006	—	Indiana University	Completed	No outcome recorded
—	NCT00028314	Mar 2002 → Mar 2005	HIV wasting syndrome, lipodystrophy	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00096850	? → Dec 2007	HIV infectious disease, tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase not stated1 trial
—	NCT00046345	May 2002 → Jul 2003	HIV infectious disease	Bristol-Myers Squibb	No longer available	No outcome recorded

Also used as a comparator or background therapy in 81 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 112 trials
Phase 1	NCT02556268 Background	Feb → Dec 2016	—	Bayer	Completed	No outcome recorded
Phase 1	NCT01759875 Comparator	Jan 2013 → Jan 2014	—	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT01404572 Comparator	Aug → Sep 2011	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT01458769 Comparator	Dec 2010 → Apr 2011	—	Concert Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00833482 Comparator	Sep 2009 → Jul 2010	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00646776 Comparator	Apr → Aug 2008	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00518297 Comparator	Aug → Dec 2007	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00362726 Comparator	Sep → Nov 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00357188 Comparator	Jul → Sep 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00357240 Comparator	Jun → Aug 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00357721 Comparator	Jun → Sep 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT00365339 Comparator	Apr → Jun 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT00411957 Comparator	Jan 2007 → Jan 2008	HIV infectious disease	The HIV Netherlands Australia Thailand Research Collaboration	Completed	No outcome recorded
Phase 210 trials
Phase 2	NCT06338826 Background	Feb 2025 → Sep 2027 expected	HIV infectious disease	ANRS, Emerging Infectious Diseases	Not yet recruiting	No outcome recorded
Phase 2	NCT02116660 Comparator	Sep 2014 → Jul 2017	HIV infectious disease	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT01803074 Background	Apr 2013 → Nov 2014	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2	NCT01384734 Comparator	Jul 2011 → Feb 2013	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2	NCT00943540 Background	Jul 2009 → Dec 2010	HIV infectious disease	Radboud University Medical Center	Completed	No outcome recorded
Phase 2	NCT00892437 Background	May → Dec 2009	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 2	NCT00827112 Background	Mar 2009 → Jul 2010	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 2	NCT00768989 Comparator	Nov 2008 → Jan 2010	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 2	NCT00665847 Background	Nov 2008 → May 2011	—	Tibotec Pharmaceuticals, Ireland	Completed	No outcome recorded
Phase 2	NCT00122603 Background	Dec 2005 → Aug 2007	HIV infectious disease	French National Agency for Research on AIDS and Viral Hepatitis	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT02285114 Background	Jan 2015 → Nov 2019	—	Gilead Sciences	Completed	No outcome recorded
Phase 2/3	NCT01923311 Background	Aug 2013 → Nov 2017	AIDS	Gilead Sciences	Terminated	No outcome recorded
Phase 2/3	NCT03019783 Comparator	Dec 2011 → Jun 2015	HIV infectious disease	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 329 trials
Phase 3	NCT03631732 Comparator	Aug 2018 → Aug 2019	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT03256422 Background	Sep 2017 → Aug 2019	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT02616783 Comparator	Dec 2015 → Feb 2018	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02603107 Background	Nov 2015 → May 2017	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02605954 Comparator	Nov 2015 → Jun 2017	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02469246 Background	Jun 2015 → Dec 2017	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02397096 Background	Jun 2015 → Feb 2018	HIV infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT02269917 Comparator	Mar 2015 → Feb 2017	HIV infectious disease	Janssen R&D Ireland	Completed	No outcome recorded
Phase 3	NCT02302547 Comparator	Dec 2014 → Aug 2017	HIV infectious disease	University Hospital, Tours	Completed	No outcome recorded
Phase 3	NCT02157311 Background	Jul 2014 → Jan 2016	HIV infectious disease	ANRS, Emerging Infectious Diseases	Completed	No outcome recorded
Phase 3	NCT02121795 Background	May 2014 → Aug 2015	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT02155101 Comparator	May 2014 → Jun 2016	HIV infectious disease	University of Liverpool	Completed	No outcome recorded
Phase 3	NCT01967940 Background	Oct 2013 → May 2015	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01910402 Comparator	Aug 2013 → Sep 2015	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 3	NCT01815736 Comparator	Mar 2013 → Mar 2015	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01620944 Background	Jul 2012 → Jan 2013	HIV infectious disease	Bristol-Myers Squibb	Terminated	No outcome recorded
Phase 3	NCT01475838 Comparator	Nov 2011 → Nov 2013	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01363011 Background	May 2011 → Jan 2013	AIDS	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01252940 Background	Nov 2010 → Jan 2012	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01106586 Comparator	Apr 2010 → Sep 2011	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT01108510 Background	Apr 2010 → Nov 2011	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00874523 Comparator	Jul 2009 → Jul 2011	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 3	NCT00708162 Background	Jul 2008 → Dec 2010	HIV infectious disease	Gilead Sciences	Completed	No outcome recorded
Phase 3	NCT00389207 Comparator	Oct 2006 → Feb 2011	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00272779 Comparator	Nov 2005 → Jun 2007	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00135395 Comparator	May 2004 → Feb 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00120393 Comparator	Jan 2004 → May 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00067782 Comparator	Dec 2002 → Mar 2005	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00035932 Comparator	Nov 2001 → Jul 2003	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded

Phase 421 trials
Phase 4	NCT01902186 Background	Sep 2014 → Dec 2016	HIV infectious disease	Giovanni Di Perri	Terminated	No outcome recorded
Phase 4	NCT01829802 Background	May 2014 → Oct 2017	HIV infectious disease	Pedro Cahn	Unknown	No outcome recorded
Phase 4	NCT01599364 Background	Apr 2014 → Apr 2016	HIV infectious disease	Catholic University of the Sacred Heart	Completed	No outcome recorded
Phase 4	NCT01691794 Comparator	Nov 2012 → Oct 2014	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT01637259 Comparator	Jun 2012 → Dec 2015	HIV infectious disease, proteinuria	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT01332227 Background	Oct 2011 → Sep 2013	—	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT01307488 Background	Sep 2011 → Apr 2014	HIV infectious disease	Fundacion SEIMC-GESIDA	Completed	No outcome recorded
Phase 4	NCT01225705 Comparator	Oct 2010 → Aug 2012	HIV infectious disease, hepatitis C virus infection	University Hospital, Bonn	Withdrawn	No outcome recorded
Phase 4	NCT01105611 Comparator	Aug 2010 → Dec 2012	HIV infectious disease, hepatitis C virus infection	St. James's Hospital, Ireland	Unknown	No outcome recorded
Phase 4	NCT01102972 Comparator	Apr 2010 → Jun 2012	HIV infectious disease	ViiV Healthcare	Completed	No outcome recorded
Phase 4	NCT00762892 Comparator	Jan 2009 → Dec 2012	HIV infectious disease	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT00544128 Comparator	Oct 2007 → Feb 2012	HIV infectious disease	International Medical Center of Japan	Completed	No outcome recorded
Phase 4	NCT00552240 Comparator	Sep 2007 → Mar 2010	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00540137 Comparator	Jul 2007 → Dec 2012	HIV infectious disease	Imperial College London	Completed	No outcome recorded
Phase 4	NCT00335322 Comparator	Feb 2007 → Mar 2011	HIV infectious disease	Kirby Institute	Completed	No outcome recorded
Phase 4	NCT00384904 Comparator	Dec 2006 → Dec 2007	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT01388543 Comparator	Sep 2006 → Jun 2008	HIV infectious disease	University of Colorado, Denver	Completed	No outcome recorded
Phase 4	NCT00135356 Comparator	Jul 2005 → Jul 2007	AIDS dysmorphic syndrome	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT00084253 Comparator	Jun 2004 → Aug 2006	HIV infectious disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 4	NCT00242216 Comparator	May 2004 → Mar 2010	HIV infectious disease	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT01445223 Comparator	Apr 2004 → Dec 2009	HIV infectious disease	Göteborg University	Completed	No outcome recorded

Phase not applicable5 trials
—	NCT05044962 Comparator	Nov 2021 → Mar 2027 expected	HIV infectious disease	University of Alabama at Birmingham	Recruiting	No outcome recorded
—	NCT00916448 Comparator	May 2009 → Mar 2010	infectious disease with sepsis, multiple organ dysfunction syndrome	Radboud University Medical Center	Completed	No outcome recorded
—	NCT02102048 Comparator	Jan 2009 → Mar 2014	HIV infectious disease	University of Roma La Sapienza	Unknown	No outcome recorded
—	NCT00413153 Comparator	May 2006 → Dec 2008	HIV infectious disease	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT00192608 Background	Nov 2004 → May 2006	HIV infectious disease	Kirby Institute	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2017-12-27	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Exclusive Launch of a Generic Version of Reyataz® in the United States tevapharm.com ↗

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 200 sources stand behind the page.

Field	Value	Cited text
Known as	atazanavir	“Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗ 182 “Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ “Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted...” NCT01815736 ↗ “Following the washout period, all participants who received TAF in Part 1 and have a \> 0.5 log10 decline in HIV-1 RNA will receive...” NCT01967940 ↗ “ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as...” NCT05044962 ↗ “This 48-week randomized study examined the safety and efficacy of a switch in CART to a once-daily regimen of saquinavir (SQV), ritonavir (RTV), and atazanavir (ATV) that did...” PMID 17479946 ↗ Apr 2007 “Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the...” NCT02397096 ↗ “The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir” NCT00820118 ↗ “Boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir \[rtv\] or cobicistat \[COBI\], or lopinavir with rtv) as per current treatment regimen.” NCT02269917 ↗ “Tenofovir+Emtricitabine+Third agent (Including a ritonavir-boosted protease inhibitor : saquinavir or indinavir or fosamprenavir or tipranavir or darunavir or atazanavir or lopinavir” NCT02302547 ↗ “Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents” NCT02556268 ↗ “(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine” NCT02513147 ↗ “We enrolled women with HIV who were either ART-naive (control group; n=25), receiving efavirenz-based ART (n=25), or receiving atazanavir-ritonavir-based ART (n=24).” PMID 31498109 ↗ Sep 2019 “Atazanavir (300 mg once daily) and lopinavir (400 mg twice daily), each with low-dose ritonavir, achieved similar IQs in HIV-infected, treatment-naive patients.” PMID 22121190 ↗ Nov 2011 “Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir.” NCT01252940 ↗ “Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV” NCT02016924 ↗ “atazanavir 300 mg and ritonavir 100 mg once daily or lopinavir 400 mg and ritonavir 100 mg twice daily plus two NRTIs; boosted protease inhibitor group” PMID 40883049 ↗ Sep 2025 “Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg” NCT00708162 ↗ “PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.” NCT00884793 ↗ “switch the protease inhibitor for oral atazanavir 200 mg and ritonavir 100 mg or for atazanavir 300 mg and ritonavir 100 mg once daily” PMID 27470026 ↗ May 2016 “Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.” NCT02155101 ↗ “allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)” NCT01475838 ↗ “We investigated whether dose escalation of atazanavir/ritonavir could safely overcome the DDI with rifampicin.” PMID 37982585 ↗ May 2024 “maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD” NCT00827112 ↗ “Either Once Daily Atazanavir/Ritonavir (ATV/r) or Once Daily Darunavir/Ritonavir (DRV/r)” NCT00756730 ↗ “Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens” NCT00006604 ↗ “allowed boosted 3rd ARV agents: lopinavir (LPV), atazanavir (ATV), darunavir (DRV)” NCT02285114 ↗ “atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg” NCT01102972 ↗ “Atazanavir (ATV) 300 mg capsule administered orally once daily” NCT01108510 ↗ “Atazanavir (ATV) 300 mg capsule administered orally once daily” NCT00892437 ↗ “Atazanavir (ATV) 400 mg tablet administered orally once daily” NCT01565889 ↗ “ritonavir (RTV)-boosted atazanavir (ATV) or darunavir (DRV)” PMID 25397568 ↗ Nov 2014 “Atazanavir 300 mg capsule administered orally once daily” NCT01106586 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02616783 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02605954 ↗ “Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine” NCT02246998 ↗ “boosted atazanavir (ATV) or darunavir (DRV)” NCT02603107 ↗ “Atazanavir + Fosamprenavir + ritonavir” NCT00122603 ↗ “ritonavir-boosted atazanavir (ATV/r)” NCT02121795 ↗ “atazanavir 300mg + cobicistat 150mg” NCT02589158 ↗ “atazanavir (ATV) + ritonavir (RTV)” NCT02469246 ↗ “PI/r = atazanavir/r ou darunavir/r” NCT06338826 ↗ “boosted atazanavir (ATV)” NCT06337032 ↗ “atazanavir 300 mg daily” NCT01367236 ↗ “atazanavir (ATV)” NCT03631732 ↗ “atazanavir [ATV]” NCT00665847 ↗ “atazanavir” NCT01637259 ↗ NCT02565888 ↗ NCT00135434 ↗ NCT00007202 ↗ NCT00751153 ↗ NCT00426296 ↗ NCT00207142 ↗ NCT01511809 ↗ NCT01928407 ↗ NCT01602822 ↗ NCT01099579 ↗ NCT01335698 ↗ NCT00307502 ↗ NCT02386098 ↗ NCT00135395 ↗ NCT00362726 ↗ NCT00002240 ↗ NCT00768989 ↗ NCT02253836 ↗ NCT01445223 ↗ NCT00878306 ↗ NCT01255371 ↗ NCT00411957 ↗ NCT01691794 ↗ NCT01003990 ↗ NCT03019783 ↗ NCT00896051 ↗ NCT01225705 ↗ NCT00885482 ↗ NCT04263350 ↗ NCT01910402 ↗ NCT00335322 ↗ NCT00544128 ↗ NCT00931801 ↗ NCT00260078 ↗ NCT02116660 ↗ NCT00120393 ↗ NCT00518297 ↗ NCT00096850 ↗ NCT00357721 ↗ NCT00357604 ↗ NCT00540137 ↗ NCT04452565 ↗ NCT01274780 ↗ NCT05680792 ↗ NCT00084253 ↗ NCT00084136 ↗ NCT00084019 ↗ NCT02102048 ↗ NCT01351740 ↗ NCT00365339 ↗ NCT00280969 ↗ NCT01073761 ↗ NCT00833482 ↗ NCT00525239 ↗ NCT02257008 ↗ NCT00082394 ↗ NCT00447070 ↗ NCT00528060 ↗ NCT02566707 ↗ NCT01605084 ↗ NCT01620944 ↗ NCT01421355 ↗ NCT00384904 ↗ NCT00242216 ↗ NCT00225017 ↗ NCT02652793 ↗ NCT00357240 ↗ NCT01818856 ↗ NCT00074581 ↗ NCT00357188 ↗ NCT00883935 ↗ NCT00720590 ↗ NCT00122577 ↗ NCT00118898 ↗ NCT00552240 ↗ NCT00326716 ↗ NCT00337467 ↗ NCT02473328 ↗ NCT00413153 ↗ NCT00532168 ↗ NCT00696722 ↗ NCT00067782 ↗ NCT01829802 ↗ NCT01368783 ↗ NCT00814879 ↗ NCT00035932 ↗ NCT00811954 ↗ NCT01105611 ↗ NCT04022967 ↗ NCT00028314 ↗ NCT00757783 ↗ NCT02307656 ↗ NCT05236738 ↗ NCT00160329 ↗ NCT00646776 ↗ NCT00940771 ↗ NCT01194856 ↗ NCT00943540 ↗ NCT00869960 ↗ NCT01599364 ↗ NCT04459286 ↗ NCT00028301 ↗ NCT00013897 ↗ NCT02034838 ↗ NCT00440947 ↗ NCT00224445 ↗ NCT00013520 ↗ NCT01404572 ↗ NCT00004584 ↗ NCT01388543 ↗ NCT00028067 ↗ NCT00389402 ↗ NCT01591850 ↗ NCT03708861 ↗ NCT02542852 ↗ NCT00420355 ↗ NCT00389207 ↗ NCT00135356 ↗ NCT04468087 ↗ NCT00762892 ↗ NCT00916448 ↗ NCT01759875 ↗ NCT00874523 ↗ NCT00162149 ↗ NCT01307488 ↗ NCT01803074 ↗ NCT00046345 ↗ NCT04184869 ↗ NCT00355719 ↗ NCT00312754 ↗ NCT01902186 ↗ NCT01384734 ↗ NCT01592305 ↗ NCT01232127 ↗ NCT01332227 ↗ NCT01656109 ↗
Known as	Atazanavir (as sulfate)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	atazanavir (Reyataz, ATV)	“atazanavir (Reyataz, ATV)” NCT00884793 ↗
Known as	Atazanavir krka	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	Atazanavir mylan	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	Atazanavir so4	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	ATAZANAVIR SULFATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	Atazanavir sulfate component of evotaz	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	Atazanavir Sulphate	“Drug: Atazanavir Sulphate” NCT00357721 ↗ 1 “Drug: Atazanavir Sulphate” NCT01335698 ↗
Known as	Atazanavir viatris (previously atazanavir mylan)	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	Atazanavir-ritonavir	“Atazanavir-ritonavir” NCT01231685 ↗ 1 NCT04531072 ↗
Known as	atazanavir/r	“Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r.” NCT01923311 ↗ 2 “protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r” NCT03256422 ↗ “atazanavir/r” NCT02157311 ↗
Known as	Atazanaviri sulfas	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	Atazor	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	ATV	“Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose...” NCT00955968 ↗ 39 “This 48-week randomized study examined the safety and efficacy of a switch in CART to a once-daily regimen of saquinavir (SQV), ritonavir (RTV), and atazanavir (ATV) that did...” PMID 17479946 ↗ Apr 2007 “Concurrent atazanavir (ATV) and lopinavir/ritonavir (LPV/r) may be useful for patients with extensive antiretroviral resistance; however, limited information exists concerning...” PMID 19906626 ↗ Sep 2009 “The purpose of this study is to determine whether two drugs, atazanavir (ATV) and ritonavir (RTV), will control HIV infection when taken together without any other anti-HIV...” NCT00084019 ↗ “We therefore evaluated the PK profiles of lower than the standard doses of atazanavir/ritonavir (ATV/RTV) in 22 adult Thai patients with well-suppressed human immunodeficiency...” PMID 19118378 ↗ Dec 2008 “Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period.” NCT00896051 ↗ “receive abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily or atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily.” PMID 19358725 ↗ Apr 2009 “Cobicistat (COBI) enhances atazanavir (ATV) pharmacokinetic parameters similarly to ritonavir (RTV) in both healthy volunteers and HIV-infected adults.” PMID 27774892 ↗ 2017 “To assess safety and efficacy of a switch to unboosted atazanavir (ATV) among HIV-infected adults receiving ATV/ritonavir (r) and tenofovir” PMID 28067119 ↗ Jan 2017 “the antiretroviral drug atazanavir (ATV) increases bilirubin levels but may also increase von Willebrand factor levels.” PMID 29023508 ↗ Oct 2017 “combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects” NCT00814879 ↗ “Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)” NCT00135356 ↗ “allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)” NCT01475838 ↗ “Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone” NCT00552240 ↗ “Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens” NCT00006604 ↗ “experimental atazanavir [ATV] dose 300 mg bid + raltegravir [RAL] 400 mg bid [ATV+RAL]” PMID 22592092 ↗ May 2012 “ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF” PMID 22748590 ↗ Jun 2012 “allowed boosted 3rd ARV agents: lopinavir (LPV), atazanavir (ATV), darunavir (DRV)” NCT02285114 ↗ “Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)” NCT00440947 ↗ “Atazanavir (ATV) 300 mg capsule administered orally once daily” NCT00892437 ↗ “received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg” NCT01099579 ↗ “Atazanavir (ATV) 400 mg tablet administered orally once daily” NCT01565889 ↗ “plasma levels of atazanavir (ATV) may be higher in Koreans” NCT01368783 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02616783 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02605954 ↗ “Atazanavir (ATV) Powder Boosted With Ritonavir (RTV)” NCT01335698 ↗ “the recently developed drug atazanavir (ATV)” NCT00389402 ↗ “boosted atazanavir (ATV) or darunavir (DRV)” NCT02603107 ↗ “ritonavir (RTV)-boosted atazanavir (ATV/r)” NCT02246998 ↗ “atazanavir plus ritonavir (ATV+RTV)” NCT01910402 ↗ “atazanavir (ATV) + ritonavir (RTV)” NCT02469246 ↗ “Atazanavir (ATV) 300 mg tablets” NCT02116660 ↗ “1. Atazanavir (ATV)” NCT04468087 ↗ “atazanavir [ATV]” NCT00665847 ↗ “Atazanavir (ATV)” NCT02386098 ↗ “atazanavir (ATV)” NCT03631732 ↗ NCT01967940 ↗ NCT01363011 ↗ NCT06337032 ↗ NCT01815736 ↗
Known as	ATZ	“Step 2 is open label. Regimens include 2 or 3 nucleoside reverse transcriptase inhibitors (NRTIs) in combination with EFV, atazanavir (ATZ), ritonavir-boosted ATZ, or tenofovir...” NCT00013520 ↗ 3 “between danoprevir (DNV) when coadministered with low-dose ritonavir (r) and tenofovir disoproxil fumarate (TDF) or atazanavir (ATZ) in healthy volunteers” NCT01592305 ↗ “A drug-drug interaction between the anti-HIV drugs tenofovir DF (TDF) and atazanavir (ATZ) results in lower ATZ plasma levels” NCT01351740 ↗ “Atazanavir(ATZ) and Tenofovir(TDF)” NCT01368783 ↗
Known as	BMS-232632	“Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens” NCT00006604 ↗ 1 “Atazanavir (BMS-232632)” NCT00046345 ↗
Known as	BMS-232632-05	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	CGP-73547	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	NSC-742546	ChEMBL registry synonym — accepted as the source's own label CHEMBL1163 ↗
Known as	Reyataz	“Atazanavir (Reyataz) was the first protease inhibitor once daily approved in 2003 for the treatment of HIV patients.” NCT02473328 ↗ 9 “Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens” NCT00006604 ↗ “Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott)” NCT01599364 ↗ “Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)” NCT00355719 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02616783 ↗ “atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)” NCT02605954 ↗ “Drug: Atazanavir (Reyataz)” NCT00885482 ↗ “atazanavir (Reyataz)” NCT00426296 ↗ NCT00385645 ↗ NCT01458769 ↗
Known as	Reyataz (atazanavir)	“Reyataz (atazanavir)” NCT01902186 ↗
Action	Inhibit	“the protease inhibitor (PI) atazanavir (ATV)” NCT00006604 ↗
Modality	Other / unclassified	“ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF” PMID 22748590 ↗ Jun 2012
Route	Oral	“Active Comparator, Capsules, tablets, Oral” NCT00035932 ↗
Target	UGT1A1	“uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) enzyme pathway.(5).ATV is a known inhibitor of this enzyme pathway” NCT00814879 ↗